Furthermore, statistical significance was reached in most patient subgroups, including both age ≤ 60 and > 60 years, male gender, both AFP > 400ng/ml and ≤400 ng/ml, both Child-Pugh A and Child-Pugh B, with and without extrahepatic metastasis, with and without portal vein thrombosis, not treatment-naïve prior to sorafenib therapy, and tumor extension > 50% of the liver. This evidence concerns the gene AFP and Portal vein thrombosis.